FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800960125> ?p ?o ?g. }

• W2800960125 endingPage "7" @default.
• W2800960125 startingPage "1" @default.
• W2800960125 abstract "Atherosclerotic cardiovascular disease (ASCVD) is a major cause of death among patients with diabetes but can be improved by certain hypoglycemic agents. However, adjudicating criteria on whether improvements are a glycemic or nonglycemic effect of these agents remain unclear.Hypoglycemic agents that produce a cardiovascular benefit in nondiabetic patients are considered to do so via a nonglycemic effect. We performed a subgroup analysis for primary and secondary prevention or very high risk of ASCVD in patients with type 2 diabetes (T2DM). Where glycosylated hemoglobin (HbA1c) was reduced to the same extent in a head-to-head comparison, cardiovascular benefits were judged as a nonglycemic effect. Furthermore, by analyzing the endpoints of four important randomized controlled intensive glucose control studies, UKPDS33, ADVANCE, ACCORD, and VADT, we calculated the cut point of HbA1c reduction for a nonglycemic effect on cardiovascular benefit by hypoglycemic agents in ASCVD groups of different severities.For the ASCVD primary prevention group of T2DM, UKPDS33 indicated a reduction in HbA1c < 0.9%, and a cardiovascular benefit within 10 years was considered a nonglycemic effect. For ASCVD secondary prevention or in the very high-risk group, pioglitazone exerted a nonglycemic effect on cardiovascular benefit in nondiabetic patients with insulin resistance; metformin may exert a similar effect in T2DM patients in a head-to-head study. Analysis of T2DM intensive glucose control studies showed a reduction in HbA1c of <1.0%, and a cardiovascular benefit after approximately 5 years was deemed a nonglycemic effect.For ASCVD primary prevention in T2DM, a reduction in HbA1c < 0.9% and a cardiovascular benefit within 10 years were considered a nonglycemic effect. For ASCVD secondary prevention or in a very high-risk population, a reduction in HbA1c < 1.0% and a cardiovascular benefit within about 5 years were also considered a nonglycemic effect." @default.
• W2800960125 created "2018-05-17" @default.
• W2800960125 creator A5002005546 @default.
• W2800960125 creator A5005355969 @default.
• W2800960125 creator A5012677271 @default.
• W2800960125 creator A5020512696 @default.
• W2800960125 creator A5030908494 @default.
• W2800960125 creator A5068299119 @default.
• W2800960125 date "2018-01-01" @default.
• W2800960125 modified "2023-10-06" @default.
• W2800960125 title "Evaluation of the HbA1c Reduction Cut Point for a Nonglycemic Effect on Cardiovascular Benefit of Hypoglycemic Agents in Patients with Type 2 Diabetes Based on Endpoint Events" @default.
• W2800960125 cites W1526927233 @default.
• W2800960125 cites W172609984 @default.
• W2800960125 cites W1986699928 @default.
• W2800960125 cites W2043551382 @default.
• W2800960125 cites W2062018857 @default.
• W2800960125 cites W2064130493 @default.
• W2800960125 cites W2076353963 @default.
• W2800960125 cites W2083342497 @default.
• W2800960125 cites W2095784604 @default.
• W2800960125 cites W2114250030 @default.
• W2800960125 cites W2115653936 @default.
• W2800960125 cites W2127854619 @default.
• W2800960125 cites W2141199290 @default.
• W2800960125 cites W2142830692 @default.
• W2800960125 cites W2146264128 @default.
• W2800960125 cites W2158666727 @default.
• W2800960125 cites W2159969745 @default.
• W2800960125 cites W2188846692 @default.
• W2800960125 cites W2200208573 @default.
• W2800960125 cites W2271771390 @default.
• W2800960125 cites W2274836352 @default.
• W2800960125 cites W2282578582 @default.
• W2800960125 cites W2295467143 @default.
• W2800960125 cites W2302447233 @default.
• W2800960125 cites W2337454357 @default.
• W2800960125 cites W2341932351 @default.
• W2800960125 cites W2412800896 @default.
• W2800960125 cites W2425644022 @default.
• W2800960125 cites W2515836370 @default.
• W2800960125 cites W2519510391 @default.
• W2800960125 cites W2521673083 @default.
• W2800960125 cites W39653778 @default.
• W2800960125 doi "https://doi.org/10.1155/2018/8457538" @default.
• W2800960125 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5933032" @default.
• W2800960125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29849624" @default.
• W2800960125 hasPublicationYear "2018" @default.
• W2800960125 type Work @default.
• W2800960125 sameAs 2800960125 @default.
• W2800960125 citedByCount "4" @default.
• W2800960125 countsByYear W28009601252020 @default.
• W2800960125 countsByYear W28009601252022 @default.
• W2800960125 crossrefType "journal-article" @default.
• W2800960125 hasAuthorship W2800960125A5002005546 @default.
• W2800960125 hasAuthorship W2800960125A5005355969 @default.
• W2800960125 hasAuthorship W2800960125A5012677271 @default.
• W2800960125 hasAuthorship W2800960125A5020512696 @default.
• W2800960125 hasAuthorship W2800960125A5030908494 @default.
• W2800960125 hasAuthorship W2800960125A5068299119 @default.
• W2800960125 hasBestOaLocation W28009601251 @default.
• W2800960125 hasConcept C126322002 @default.
• W2800960125 hasConcept C134018914 @default.
• W2800960125 hasConcept C164705383 @default.
• W2800960125 hasConcept C168563851 @default.
• W2800960125 hasConcept C203092338 @default.
• W2800960125 hasConcept C2777180221 @default.
• W2800960125 hasConcept C2778384471 @default.
• W2800960125 hasConcept C2779306644 @default.
• W2800960125 hasConcept C2780323712 @default.
• W2800960125 hasConcept C2780473172 @default.
• W2800960125 hasConcept C555293320 @default.
• W2800960125 hasConcept C71924100 @default.
• W2800960125 hasConceptScore W2800960125C126322002 @default.
• W2800960125 hasConceptScore W2800960125C134018914 @default.
• W2800960125 hasConceptScore W2800960125C164705383 @default.
• W2800960125 hasConceptScore W2800960125C168563851 @default.
• W2800960125 hasConceptScore W2800960125C203092338 @default.
• W2800960125 hasConceptScore W2800960125C2777180221 @default.
• W2800960125 hasConceptScore W2800960125C2778384471 @default.
• W2800960125 hasConceptScore W2800960125C2779306644 @default.
• W2800960125 hasConceptScore W2800960125C2780323712 @default.
• W2800960125 hasConceptScore W2800960125C2780473172 @default.
• W2800960125 hasConceptScore W2800960125C555293320 @default.
• W2800960125 hasConceptScore W2800960125C71924100 @default.
• W2800960125 hasLocation W28009601251 @default.
• W2800960125 hasLocation W28009601252 @default.
• W2800960125 hasLocation W28009601253 @default.
• W2800960125 hasLocation W28009601254 @default.
• W2800960125 hasLocation W28009601255 @default.
• W2800960125 hasOpenAccess W2800960125 @default.
• W2800960125 hasPrimaryLocation W28009601251 @default.
• W2800960125 hasRelatedWork W2070740840 @default.
• W2800960125 hasRelatedWork W2113209045 @default.
• W2800960125 hasRelatedWork W2155334925 @default.
• W2800960125 hasRelatedWork W2370360514 @default.
• W2800960125 hasRelatedWork W2556250268 @default.
• W2800960125 hasRelatedWork W2580091266 @default.
• W2800960125 hasRelatedWork W2883675297 @default.

• next